MedPath

Multicentric Study an Endoscopic Treatment of Digestive Neoplasia by Submucosal Dissection Evaluation of a New Water Jet System

Not Applicable
Completed
Conditions
Stomach Neoplasm
Rectal Neoplasm
Intestinal Neoplasm
Interventions
Procedure: endoscopic sub-mucosal dissection
Registration Number
NCT01910974
Lead Sponsor
Hôpital Edouard Herriot
Brief Summary

safety evaluation of endoscopic sub-mucosal dissection with nestis enki2 system. This system is a new water jet system which allows to perform Endoscopic submucosal dissection with a bifunctional catheter (injection and cutting).

Detailed Description

Evaluation of the ability of this system to have a complete resection of superficial tumors of the digestive tract (that is to say a resection with free lateral and deep margins without residual tumor tissue)

Evaluation of the ability of such system to inject a viscous macromolecular solution of glycerol (glycerol mix: Glycerol 10 %, Fructose 5 %, saline solution 0.9%)(27. Fujishiro M, Yahagi N, Kashimura K, et al. Comparison of various submucosal injection solutions for maintaining mucosal elevation during endoscopic mucosal resection. Endoscopy. 2004;36:579-583.)

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • OVER 18 YEARS OLD
  • PATIENTS AGREED WITH THE STUDY
  • SCORE ASA 1 OR 2
  • Patient recorded in a social safety organism
  • patients presenting with superficial lesions with an endoscopic indication of resection
Exclusion Criteria
  • under 18 years old
  • Patients not agreed with the study
  • pregnant women
  • patient included in an another study
  • medical treatments (radiotherapy, surgery endoscopis treatements) before the intervention
  • coagulation disorders
  • score asa over 3
  • patients with another neoplasic lesion

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
endoscopic sub-mucosal dissectionendoscopic sub-mucosal dissection-
Primary Outcome Measures
NameTimeMethod
SAFETY THAT IS TO SAY PERFORATION RATE AND delayed BLEEDING ONE18 months

inclusion duration is about 6 months the following period will be about 12 months so a total duration of 18 months

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

NESTIS

🇫🇷

Lyon, Rhone Alpes, France

© Copyright 2025. All Rights Reserved by MedPath